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Abstract
Background: Lung nodules caused by mycobacteria can resemble lung cancer on chest imaging. The advent of
lung cancer screening with low-dose Computed Tomography is accompanied by high false-positive rates, making it
necessary to establish criteria to differentiate malignant from benign nodules.
Methods: We conducted a retrospective case–control study of 52 patients with mycobacterial lung nodules and
139 patients with lung cancer, diagnosed between 2010 and 2012. We compared clinical and radiographic
characteristics to identify predictors of disease by univariate and multivariate analysis. The discriminatory power of
maximum Standardized Uptake Values from Positron-Emission-Tomography was also evaluated.
Results: Several variables were correlated with a diagnosis of mycobacterial infection or lung cancer on univariate
analysis. Such variable include smoking status and history, lesion size and imaging evidence of tree-in-bud opacities,
lymphadenopathy or emphysema on computed tomography. Upon author consensus, the most clinically-relevant
variables were selected to undergo multivariate analysis. A history of current or former smoking [OR 4.4 (95 % CI
1.2–15.6) and 2.7 (95 % CI 1.1–6.8), respectively P = 0.04] was correlated with diagnoses of lung cancer. Contrarily,
the presence of tree-in-bud opacities was less likely to be correlated with a diagnosis of malignancy [OR 0.04
(95 % CI 0.0–1.0), P = 0.05]. Additionally, higher maximum standardized uptake values from positron emission
tomography were associated with malignancy on multivariate analysis [OR 1.1 (95 % CI 1.0–1.2), P = 0.04]; but
the accuracy of the values in differentiating between diseases was only 0.67 as measured by the area under
the curve. Lesion size was not independently associated with diagnosis [OR 0.5 (95 % CI 0.2–1.2), (P = 0.12)].
Conclusions: Establishing the likelihood of malignancy for lung nodules based on isolated clinical or radiographic
criteria is difficult. Using the variables found in this study may allow clinicians to stratify patients into groups of high
and low risk for malignancy, and therefore establish efficient diagnostic strategies.
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Background
Recent clinical trials have demonstrated substantial mor-
tality benefit from using low-dose chest Computed
Tomography to screen for lung cancer in high-risk
patients [1, 2]. Most U.S. guidelines now recommend
this strategy [3–5]. Despite these advantages; screening
with computed tomography frequently identifies non-
malignant lung lesions, resulting in false positive rates
that are as high as 70 % [2, 6–8]. In the large, random-
ized National Lung Screening Trial, many lung nodules
were ultimately nonmalignant, but the eventual histo-
logic diagnoses of these nodules have not been reported.
Since the implementation of routine screening of lung
cancer will most likely be accompanied by an increase in
the rates of detection of benign nodules, including those
cause by mycobacteria, a condition frequently encoun-
tered by infectious diseases specialists, differentiating
malignant from infectious nodules before invasive lung
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sampling, will become increasingly important in the
years to come [1].
The clinical spectrum of mycobacterial lung disease is
broad and ranges from a state of asymptomatic-carrier
based on culture positivity, to a wasting illness with cavi-
tary lung lesions that mimic tuberculosis. The radio-
graphic spectrum of mycobacterial lung infection on
chest imaging is broad and includes solitary pulmonary
nodules [9, 10] that mimic malignancy [11, 12], in
addition to the more classic nodular-bronchiectatic and
cavitary presentations. Although descriptions of the
manifestations of mycobacterial lung disease on Com-
puted Tomography (CT) [9, 13], and Positron-Emission
Tomography (PET) [14, 15] exist; a direct comparison
between radiographic and clinical characteristics of lung
nodules caused by mycobacteria and cancer has not
been performed. In this study we compared such charac-
teristics in consecutive patients evaluated for suspicious
lung lesions in our center.
Our goal was to describe clinical and radiographic
differences between patients with mycobacterial or
malignant lung nodules that can serve as predictors
of the etiology of suspicious nodules before tissue
sampling is performed. We identify relevant clinical
and radiographic variables and determine their association
with the occurrence of each diagnosis. We believe such
variables can assist clinicians evaluating the etiology of
pulmonary nodules detected incidentally or during screen-
ing for lung cancer.
Methods
Memorial Sloan Kettering Cancer Center is a 432-bed,
tertiary-care center in New York City that serves pa-
tients suffering from lung malignancies. We conducted a
case–control; retrospective study that included patients
diagnosed with suspicious pulmonary lesions between
April 2010 and April 2012, whose diagnosis was not a
result of lung cancer screening. The Memorial Sloan
Kettering Cancer Center Institutional Review Board
approved this study and a waiver for the need to
obtain informed consent from patients was issued
(approval#WAC-0150-12 for review of existing data).
Patient records and information was anonymized and
de-identified prior to analysis. The study was con-
ducted in accordance with the amended declaration
of Helsinki. Subjects were identified according to the
following definitions:
Nodular lung disease Defined as the presence of one or
more lesions within and surrounded by lung paren-
chyma [16] on chest imaging. Patients with lesions ten
or more millimeters in longest diameter were included.
Lesions 30 mm or longer in biggest diameter were
further classified as lung masses.
Mycobacterial nodular lung disease (cases) Diagnostic
criteria from the American Thoracic Society and Infec-
tious Diseases Society of America for Non-Tuberculous
Mycobacterial lung disease were used [17]. Patients with
lesions caused by Mycobacterium tuberculosis were
included and similar criteria were used. The case defin-
ition included 1) lung histopathology consistent with
granulomatous inflammation; and 2) microbiologic evi-
dence of mycobacterial infection with one or more of
the following: a) Positive mycobacterial stain in lung
tissue (Ziehl-Nielsen or Fite); b) Positive mycobacterial
culture from lung tissue; c) positive mycobacterial
culture from one bronchoalveolar lavage/wash or at least
two sputum samples. Patients were excluded if malig-
nancy was diagnosed on the same lung sample.
Malignant nodular lung disease (controls) Patients in
this category included those who were diagnosed with
primary lung cancer; excluding patients diagnosed with
recurrent lung cancer (lung tumors diagnosed within the
prior five years), or pre-existing lung cancer (lung
tumors actively being treated at the time of diagnosis).
Data collection
Patients were identified using electronic searches in vari-
ous databases. A microbiology database search identified
all patients with reports of positive mycobacterial
cultures. Only patients with positive samples from lung
tissue, bronchoalveolar lavage/wash or sputum were
considered for inclusion. Searches within infection
control and pathology databases identified patients
with granulomatous inflammation and positive myco-
bacterial stains on histopathology, but whose cultures
were negative or not performed. A search within the
institutional tumor database identified patients diagnosed
with lung cancer during the period of interest. Collected
data on individual patients included age, gender, race,
height, weight, body mass index; dates of chest imaging,
tumor diagnosis; diagnostic procedure(s) and their re-
spective dates.
A review of electronic medical records identified
additional variables of interest. Patients were considered
symptomatic if they had any type of respiratory or relevant
non-respiratory symptoms (fever, weight loss or night
sweats) at the moment of diagnosis or during six months
prior. Patients were categorized as born in the United
States or elsewhere. Imaging variables were collected from
reports of CT and PET performed closest to the date of
diagnosis. Variables from tomography included number
and size of lung lesions, presence of cavitation, spiculation
or surrounding ground glass opacities. The presence of
abnormalities in the surrounding lung parenchyma and
thoracic structures was recorded, including: bronchi-
ectasis, tree-in-bud inflammation, lymphadenopathy,
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atelectasis, emphysematous lung, and pleural effusion.
For PET, we recorded whether lesions were hypermet-
abolic and if so, the maximum standardized uptake
value (SUV Max) of the dominating lesion.
Microbiology
Processing of specimens included an initial Auramine-
Rhodamine smear; followed by inoculation into plates
with Middlebrook/7H11 agar, and a mycobacterial
growth indicator tube. Plates were incubated at 35 °C
with 5-7 % CO2; and mycobacterial growth indicator
tubes were placed on a BACTEC™ MGIT™ instrument
for six weeks. Any resulting growth was smeared and
stained with the Kinyoun technique; followed by probe
testing (M. tuberculosis-complex, M. avium-complex, M.
kansasii and M. gordonae; AccuProbe, Gen-Probe™).
Isolates that were negative by all four probes were sent
for 16S rRNA sequencing for final identification.
Statistical analysis
Univariate associations between case/control groups and
clinical and radiographic characteristics were evaluated
using Fisher’s exact test for categorical variables,
Mantel-Haenszel test for trend for ordinal variables and
the Wilcoxon rank sum test for continuous variables.
Selected clinical and radiographic characteristics that
were significantly associated with case/control group
univariately were further examined in a multivariate
logistic regression model. A receiver operating character-
istic curve was generated to examine the accuracy of SUV
max in differentiating between lung malignancy and
mycobacterial infection. All calculations were performing
using SAS version 9.2 (SAS Institute, Cary, NC).
Results
During the period of interest, 534 positive mycobacterial
cultures corresponding to 333 patients were reported by
the microbiology laboratory. Infection control and path-
ology databases identified ten additional patients. An ini-
tial chart review excluded 291 patients. One hundred
and sixty two lacked histopathological analysis and 90
had alternative diagnoses on histopathological analysis
including malignancy, non-mycobacterial infections
(Pneumocystis, Coccidioides), pneumonitis, or inconclu-
sive biopsy results.
During the same time period, 742 patients were diag-
nosed with lung cancer. Due to the large number of
patients in the control group, a representative-random
sample of 150 patients was generated by the statistician
(ER). A subsequent review of electronic medical records
excluded 11 patients. Four of them had pre-existing lung
cancer and seven had recurrent lung cancer. One
hundred and thirty-nine patients were included in the
final analysis.
Baseline demographic characteristics of patients are
summarized in Table 1. Patients from both groups were
similar in terms of age, gender, place of birth and ethni-
city. The majority of patients were female, and the most
common ethnicity was non-Hispanic white. The median
Charlson Comorbidity Index (CCI) was similar in both
groups. However, Chronic Obstructive Pulmonary Disease
(COPD) was more prevalent amongst patients diagnosed
with lung cancer (23.0 % vs 7.7 %, P = 0.02). The majority
of patients in both groups were asymptomatic at the time
of diagnosis [thirty-one (59.6 %) in the cases group vs
seventy-three (52.5 %) in the controls group, P = 0.42,
Table 1]. For symptomatic patients, the most commonly
reported symptoms are described in Table 1. Notably,
among symptomatic patients there was no difference
between cases and controls in the incidence of cough
(P = 0.52).
Procedures performed for lung tissue sampling are
described in Table 1. The majority of patients in the
mycobacterial group (28 patients, 55 %) underwent
thoracotomy and lung wedge biopsy. This was followed
by transthoracic lung biopsy (18 patients, 35 %) and
transbronchial biopsy (5 patients, 10 %). One patient
underwent a lobectomy. Patients in the lung cancer
group underwent surgical and transthoracic lung biopsy
at similar rates (51 patients, 37 % and 53 patients, 38 %
respectively), and a minority underwent bronchoscopy
and transbronchial lung biopsy (35 patients, 25 %).
Lung tissue sampling and histopathology analysis
was performed in all of the patients diagnosed with
mycobacterial disease. Core biopsies were available in
forty-three patients, and cytological analysis of lung
aspirate was available in the remaining nine patients.
All patients with mycobacterial infection had evidence
of granulomatous inflammation. Of those who had
core biopsies, thirty-six had evidence of necrotizing
granulomas (83.7 %), six had evidence of non-necrotizing
granulomas (14 %) and one patient had evidence of both
necrotizing and non-necrotizing granulomas (2.3 %). All
the patients who had cytological analysis performed had
cytological elements suggestive of granulomatous
inflammation. Fite or Ziehl-Neelsen acid fast stains
were performed in fifty one out of the fifty two avail-
able surgical specimens, and were positive in twenty
three (45 %) patients, with Fite being the most com-
mon positive stain.
Of the types of Mycobacteria isolated from respiratory
samples, Mycobacterium avium-complex (MAC) was the
most common isolated species (81 %) followed by Myco-
bacterium tuberculosis (9 %), Mycobacterium xenopi
(4 %) and Mycobacterium haemophilum (4 %). In two
cases (2 %), the Auramine-Rhodamine stain was positive
but cultures were sterile. The majority of patients (79 %)
had mycobacteria recovered from lung tissue, followed
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by bronchoalveolar lavage/wash (11 %) and induced spu-
tum (8 %). Regarding the distribution of the types of
lung cancer, adenocarcinoma was most common (68 %),
followed by squamous cell carcinoma (14 %), small cell
carcinoma (7 %), large cell carcinoma (3 %), carcinoid
tumor (3 %), others (including adenosquamous, pleo-
morphic and pseudosarcomatous carcinoma) (3 %) and
non-small cell carcinoma (2 %).
Table 2 summarizes the radiographic findings in both
groups. Most of the patients in both groups had solitary
nodules within a single lobe [40 (76.9 %) patients in the
mycobacterial group and 121 (87.1 %) patients in the
lung cancer group]. Although there was a slightly higher
percentage of patients with solitary nodules in the lung
cancer group, this difference was not statistically signifi-
cant (P = 0.12, Table 2). However; mycobacterial lung
lesions corresponded more commonly to lung nodules
(<3 cm); whereas lesions caused by lung cancer corre-
sponded more commonly to masses (≥3 cm) (P < 0.0001,
Table 2). The median maximum diameter of mycobac-
terial lesions was also shorter than malignant lesions
(20 mm vs 30 mm respectively, P = 0.0005, Table 2).
Lesions caused by mycobacteria were commonly asso-
ciated with bronchiectasis (25.0 % vs 6.5 %, P = 0.001,
Table 2) and a tree-in-bud pattern in the surrounding
lung parenchyma (4.7 % vs 0, P < 0.0001, Table 2). In
contrast, intrathoracic lymphadenopathy (40.3 % vs
15.4 %, P = 0.001, Table 2) and emphysema (36.0 % vs
17.3 %, P = 0.01, Table 2) were more commonly seen in
patients diagnosed with lung cancer. Atelectasis and
pleural effusions were more commonly found in lung
cancer patients; however this difference did not reach
statistical significance.
Maximum standardized uptake values from PET were
available for 43 (82.7 %) cases and 137 (98.5 %) controls.
Lesions caused by lung cancer had a higher median SUV
max value than those caused by mycobacteria (SUV
max = 9.5 vs SUV max = 6.5, respectively; P = 0.001,
Table 2). Results of a receiver operating characteristic
curve of SUV max values from PET scan are shown in
Additional file 1. The area under the curve was 0.67,
reflecting a poor level of accuracy for differentiating
lesions caused by mycobacteria and lung cancer.
However, none of the lesions caused by Mycobacteria
had SUV max values ≥ 16.
Analysis of the relationship between SUV max value
and lesion size showed no differences between the median
SUV max of nodular lesions caused by lung cancer or
mycobacterial infection [median SUV max 6 (IQR 3–8.1)
vs 6.2 (IQR 3–8.5), respectively]. However, the median
SUV max of masses caused by lung cancer was higher
than masses caused by mycobacteria [median SUV max
12.9 (IQR 9.5–16.8) vs 8.2 (IQR 6.1–11.1) respectively]. A
graphic representation of the distribution of SUV max





Age, y, median (range) 67 (4–91) 67 (38–90)
Male 17 (32.7) 65 (46.8)
Female 35 (67.3) 74 (53.2)
CCI, Median (IQR) 1 (0–2) 1 (0–2)
Race
Non-Hispanic white 42 (80.8) 120 (86.4)
Asian 4 (7.7) 7 (5.0)
Hispanic 4 (7.7) 7 (5.0)
Black 1 (1.9) 5 (3.6)
Unknown 1 (1.9) 0
Place of birth
United States 40 (77.0) 97 (70.0)
Non-United States 12 (23.0) 42 (30.0)
Symptom status
Asymptomatic 31 (59.6) 73 (52.5)
Symptomatic 21 (40.4) 66 (47.5)
• Cough 24 (46.2) 72 (51.8)
• Dyspnea 10 (19.2) 49 (35.3)
• Hemoptysis 2 (3.8) 13 (9.4)
• Wheezing 2 (3.8) 8 (5.8)
• Self-reported fever 3 (5.8) 2 (1.4)
• Involuntary weight loss 6 (11.5) 11 (7.9)
• Chest pain 3 (5.8) 0
• Night sweats 2 (3.8) 1 (0.7)
Indication for imaging
Symptom evaluation 21 (40.4) 66 (47.5)
Cancer surveillance 13 (25.0) 23 (16.5)
Incidental finding 18 (34.6) 50 (36.0)
Diagnostic procedure
Thoracotomy and biopsy 29 (55.0) 51 (37.0)
Transthoracic lung biopsy 18 (35.0) 53 (38.0)
Bronchoscopy and transbronchial
lung biopsy
5 (10.0) 35 (25.0)
Selected Comorbidities
Hypertension 24 (46.2) 65 (46.8)
COPD 4 (7.7) 32 (23.0)
Diabetes 4 (7.7) 21 (15.1)
Connective tissue disorder 2 (3.8) 5 (3.6)
Asthma 1 (1.9) 9 (6.5)
Mitral valve prolapse 3 (5.8) 2 (1.4)
Data are presented as No. (%) unless otherwise specified. Abbreviations: CCI
Charlson Comorbidity Index, COPD Chronic obstructive pulmonary disease
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Table 2 Radiographic findings on chest Computed Tomography and Positron-Emission-Tomography
Finding Category Mycobacterial lung disease (52) Lung cancer (139) P-value
Multiple lobes affected No 40 (76.9) 121 (87.1) 0.12
Yes 12 (23.1) 18 (12.9)
Number of lobes affecteda Two 6 (50.0) 14 (77.8) 0.001
Three 0 4 (22.2)
Four 5 (41.7) 0
Five 1 (8.3) 0
Localization of dominating lesionb Left lower lobe 6 (15.0) 11 (9.1)
Left upper lobe 8 (20.0) 30 (24.8)
Right lower lobe 3 (7.5) 25 (20.7)
Right middle lobe 5 (12.5) 8 (6.6)
Right upper lobe 18 (45.0) 47 (38.8)
Size of Dominating lesion Maximum length in mm (Median, IQR) 20 (14–26) 30 (19–49) 0.0005
Lesion type Nodule 43 (82.7) 67 (48.2) <0.0001
Mass 9 (17.3) 72 (51.8)
Positron-Emission-Tomography findings
Examined variable Category Mycobacterial Lung Disease (52) Lung Cancer (139) P-value
PET available Yes 43 (82.7) 137 (98.6)
No 9 (17.3) 2 (1.4)
Hypermetabolic lesion Yes 42 (97.7) 125 (92.6)
No 1 (2.3) 10 (7.4)
Result not available 0 2
SUV Max Median (IQR) 6.5 (4.0–8.7) 9.5 (4.9–14.5) 0.001
Lung parenchyma and thoracic structures
Total findings
Bronchiectasis 22 (11.5) 13 (25.0) 9 (6.5) 0.001
Intrathoracic lymphadenopathy 64 (33.5) 8 (15.4) 56 (40.3) 0.001
Cavitary lesion 19 (9.9) 7 (13.5) 12 (8.6) 0.41













Table 2 Radiographic findings on chest Computed Tomography and Positron-Emission-Tomography (Continued)
Emphysematous lung 59 (30.9) 9 (17.3) 50 (36.0) 0.01
Perilesional ground glass 21 (11) 3 (5.8) 18 (12.9) 0.20
Spiculated lesion 44 (23) 15 (28.8) 29 (20.9) 0.25
Tree-in-bud opacities 9 (4.7) 9 (17.3) 0 <0.0001
Pleural effusion 15 (7.9) 1 (1.9) 14 (10.1) 0.07
Data are presented as No. (%) unless otherwise specified. Abbreviations: SUV Max Maximum Standardized Uptake Value, PET Positron-Emission Tomography
aIn patients with multiple lobes affected













values stratified by lesion (nodule vs mass) and underlying
disease types (mycobacterial infection vs cancer) is shown
in Fig. 1. A scatterplot of SUV max and corresponding le-
sion size demonstrated no relationship between the degree
of hypermetabolism and the size of any given lesion, Fig. 2.
These results therefore suggest that the observed higher
degree of hypermetabolism exhibited by malignant nod-
ules cannot be explained solely by the observed difference
in size between neoplastic and mycobacterial lesions.
Analysis of clinical variables is shown in Table 3.
Patients with lung cancer were more likely to be current
smokers compared to patients diagnosed with mycobac-
terial lung disease (7.7 % of cases vs 27.3 % of controls,
P = 0.005, Table 3). The cumulative tobacco exposure
was also significantly higher in patients with lung cancer
compared to those with mycobacterial infection (median
40 pack-years vs 23 pack-years, respectively, P < 0.0001,
Table 3). Patients with lung cancer had a higher average
body mass index compared to subjects with mycobacter-
ial lung nodules (Mean BMI 27.3 kg/m2 vs 25.1 kg/m2,
P = 0.01, Table 3). Case-patients were more likely to have
a history of cancer than controls (50.0 % vs 25.9 %,
P = 0.003, Table 3); however, the majority of patients
with any history of cancer in both groups had no
evidence of active malignancy at the time of diagnosis
(76.9 % in the mycobacterial lung disease group vs
77.8 % in the lung cancer group, P = 1.0, Table 3).
Upon authors’ consensus, variables thought to be most
clinically-relevant including smoking status at the time
of diagnosis, lesion type (nodule vs mass), SUV max
value, and tree-in-bud in the surrounding parenchyma,
were selected for multivariate analysis. The number of
patients in the study did not allow inclusion of all the
significant variables from univariate analysis for multi-
variate analysis. Results are shown in Table 3 and are
presented as adjusted odds ratios (OR). Factors associ-
ated with increased odds of a lesion being lung cancer
were history of smoking at the time of diagnosis (current
smoker vs never smoker: OR 4.4, 95 % CI 1.2–15.6;
former smoker vs never smoker: OR 2.7, 95 % CI 1.1–
6.8; P = 0.04, Table 3); and unit increases of SUV max
value of dominating lesions (per unit increase in SUV
max: OR 1.1, 95 % CI 1.0–1.2, P = 0.04, Table 3). In con-
trast, the odds of receiving a diagnosis of lung cancer
were significantly lower in the presence of a tree-in-bud
inflammatory pattern in the surrounding parenchyma
(OR 0.04, 95 % CI 0.0–1.0, P = 0.05). Lesion size was not
independently associated with lung cancer (P = 0.12).
Fig. 1 Maximum standardized uptake value by disease and lesion type
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Discussion
Diagnosing mycobacterial lung nodules prior to tissue
sampling is challenging due to several factors, including
the relative lack of awareness of this type of mycobacterial
infection. For the fibrocavitary and nodular/bronchiectatic
forms of the disease, clinical, radiographic and microbio-
logic criteria can be more easily applied [17]. In the case
of nodular disease, the frequent absence of systemic or
pulmonary symptoms impede collection of microbiologic
data, which would provide early clues to the possibility of
mycobacterial infection as the etiology of lung nodules
[18]. Such microbiologic data is often not collected in
cases of purely nodular lung disease due to the broad
differential diagnosis and the priority of excluding lung
cancer. Similar to previous studies, all mycobacterial lung
lesions in our series were suspicious for malignancy based
on their radiographic appearance [12, 19, 20]. There have
been no previously described clinical and radiographic
criteria that can reliably differentiate malignant lung
lesions from those caused by mycobacteria [20]. Identify-
ing such factors will become increasingly important as
computed tomography screening for lung cancer becomes
more widespread and more false-positive results are
generated [21].
Mycobacteria are common causative organisms of lung
nodules as reflected by previous reports that describe in-
fection as a common etiology (~20 %) of suspicious lung
nodules, with around 25 % of such infections corre-
sponding to mycobacteria [22]. Additionally, an increase
in the incidence and prevalence of mycobacterial infec-
tions in different areas of the world has been described
[23–25]; likely due to increased awareness of their role
as human pathogens [24]; and possibly due to environ-
mental and pathogen-specific factors [26]. Nonetheless,
lung cancer screening undoubtedly will be associated
with further increase in the numbers of mycobacterial
infections, making it necessary to better understand the
manifestations of this type of disease. In our study, we
describe clinical and radiographic parameters that may
help clinicians suspect mycobacterial infection or malig-
nancy prior to lung tissue sampling.
Patients with mycobacterial lung disease were com-
monly former or never smokers and had a comparative
lower tobacco exposure, compared to patients with lung
cancer. The latter also had a higher prevalence of COPD.
This scenario is in accordance with clinical guidelines
that recommend lung cancer screening in patients with
a tobacco exposure ≥ 30 pack-years [5, 7]. Additionally,
Fig. 2 Scatterplot of maximum standardized uptake values and largest lesion size (in millimeters)
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most cases of mycobacterial infection were diagnosed
during cancer surveillance or incidentally, in patients
who were asymptomatic.
Several radiographic characteristics did differentiate
between mycobacterial and malignant nodules. Malig-
nancy commonly corresponded to larger lesions, but this
correlation was only observed in a univariate analysis.
Changes in the lung parenchyma and thoracic structures
provided more significant clues to differentiate mycobac-
terial from neoplastic lesions. Although, a tree-in-bud
inflammatory pattern on the lung parenchyma was only
present in a minority of patients with mycobacterial dis-
ease, it was never found in association with a malignant
nodule. This association was significant in both univari-
ate and multivariate analyses and should be considered a
clue for suspecting mycobacterial infection.
Even though PET scan has been postulated as a poten-
tial tool for the diagnosis and monitoring of infectious
and malignant lesions [27–29], in our study, it lacked
specificity for differentiating neoplasia from mycobacter-
ial infection. Such findings differ from previous studies
that describe PET as a useful tool in differentiating
benign from malignant lesions [14, 30]. We encountered
that SUV max values ≥ 16 had the highest specificity and
positive predictive value for diagnosing lung cancer; and
it is possible that studies that include other types of
infection may show different results regarding PET
performance. This underlies the importance of improv-
ing the specificity of chest imaging during lung cancer
screening, in order to efficiently differentiate lung malig-
nancies from benign lesions.
Strengths of our study include the availability of histo-
pathology, culture and imaging results for all patients,
allowing inclusion of proven cases of mycobacterial infec-
tion. The nature of our institution as a reference center
for the diagnosis of lung cancer also favored a higher
number of cases of mycobacterial lung nodules. Limita-
tions included the retrospective nature of the study, which
prevented a more extensive assessment of patients’ symp-
toms; as well as revision of existing imaging results.
Conclusions
In our study, we found that individual clinical and
imaging characteristics are poor predictors of cancer or
mycobacterial disease in patients with lung nodules. Our
data suggests that a diagnosis of lung cancer would be
Table 3 Univariate and multivariate analysis of selected clinical and radiographic variables
Univariate analysis Multivariate analysis
Risk Factor Category Mycobacterial lung
disease (52)
Lung Cancer (139) P-value OR for lung cancer vs mycobacterial
lung disease (95 % CI)d
P-value
Smoking status Current 4 (7.7) 38 (27.3) 0.005 4.4 (1.2–15.6) 0.04
Former 33 (63.5) 78 (56.1) 2.7 (1.1–6.8)
Never 15 (28.8) 23 (16.5) 1
Cumulative smokinga Median (IQR) 23 (5–39) 40 (30–58) <0.0001
Body mass index Mean (STD) 25.1 (4.9) 27.3 (5.3) 0.01
History of cancer No 26 (50.0) 103 (74.1) 0.003
Yes 26 (50.0) 36 (25.9)
Number of tumorsb 0 26 (50.0) 103 (74.1) 0.004
1 23 (44.2) 29 (20.9)
2+ 3 (5.8) 7 (5.0)
Active cancerc No 20 (76.9) 28 (77.8) 1.0
Yes 6 (23.1) 8 (22.2)
Lesion type Nodule (<3 cm) 43 (82.7) 67 (48.2) <0.0001 0.5 (0.2–1.2) 0.12
Mass (≥3 cm) 9 (17.3) 72 (51.8) 1
SUV max Median (IQR) 6.5 (4.0–8.7) 9.5 (4.9–14.5) 0.001
Per unit increase 1.1 (1.0–1.2) 0.04
Tree-in-bud opacities in CT No 43(82.7) 139 (100) <0.0001 1 0.05
Yes 9 (17.3) 0 0.04 (0.0–1.0)
Data are presented as No. (%) unless otherwise specified. Abbreviations: BMI Body Mass Index, OR Odds Ratio, CI Confidence Interval, SUV Max Maximum
Standardized Uptake Value
aExpressed in pack-years
bIn patients with a history of cancer
cOf those patients with a history of cancer
dResults presented as adjusted OR
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favored for large lesions; occurring in current smokers;
and that have very high SUV max values on PET. In
contrast, mycobacterial infection should be suspected
when a tree-in-bud pattern is seen in association with
lung nodules in patients with a less significant degree of
smoking. Larger clinical studies are needed in order to
establish additional clinical and radiographic parameters
that help establish the likelihood of malignancy of newly
diagnosed lung nodules, and subsequently stratify the
risk of individual patients, allowing a rapid and efficient
diagnosis. As lung cancer screening becomes more
prevalent, these criteria can be refined further as more
pathologic data become available on asymptomatic lung
nodules detected by tomography.
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